Argus analyst David Coleman maintained a Buy rating and $60 price target on Altria Group. In a research note to investors, Coleman says that while Altria is facing pressure from legislative efforts to limit sales of e-vapor products in the wake of recent deaths associated with vaping devices, he believes that consumers will continue to view vaping products as a more acceptable nicotine delivery system than traditional cigarettes or chewing tobacco, and that the use of these products will continue to grow despite legislative restrictions. The analyst notes that Altria still derives most of its revenue from smokeable products, including brands like Marlboro, and that smokeless products accounted for just 12% of net revenue in Q2.